Spherix Press Releases

2008

::Nov 19:: Spherix Stockholders Authorize Potential Reverse Stock Split BETHESDA, MD, Spherix Incorporated (Nasdaq:SPEX) reported that at a special meeting of stockholders held on November 17, 2008, the stockholders authorized the Board of Directors to effect a reverse split of its common stock at any time within the next twelve (12) months at a ratio ranging from 1:5 to 1:20. The Board of Directors will be assessing the appropriateness and size of a reverse split. Full Press Release»

::Nov 13:: Spherix Reports 3rd Quarter Earnings BETHESDA, MD, Spherix Incorporated (Nasdaq:SPEX) reported a net loss for the three and nine months ended September 30, 2008 of $1.7 million ($0.12 per share) and $4.8 million ($0.34 per share), respectively. Full Press Release»

::Nov 10:: Spherix Transfers Stock Listing To Nasdaq Capital Market BETHESDA, MD, Spherix Incorporated (Nasdaq:SPEX) reported that the Nasdaq Stock Market has approved its application to transfer the listing of its common stock from the Nasdaq Global Market to the Nasdaq Capital Market. The common stock is expected to commence trading on the Nasdaq Capital Market on November 11, 2008. Full Press Release»

::Nov 7:: Patient Recruitment Begins In India For Phase 3 Diabetes Trial BETHESDA, MD, Spherix Incorporated (NASDAQ/SPEX) reported that patient recruitment for its Phase 3 clinical trial of its potential type 2 diabetes drug, Naturlose®, has begun in India. Expectations for India are to provide more than 300 patients spread across 35 sites for the pivotal Phase 3 trial. Full Press Release»

::Oct 23:: Spherix Receives NASDAQ Letter Extending Minimum Bid Price Compliance Period BETHESDA, MD, Spherix Incorporated (NASDAQ/SPEX) reported that on October 22, 2008, it received written notification from NASDAQ advising the Company that, because of the current instability in the financial markets, NASDAQ has suspended enforcement of the bid price and market value requirements for continued listing on its Global Market. Full Press Release»

::Spet 8:: Spherix Incorporated To Seek Stockholder Approval Of Reverse Stock Spilt BETHESDA, MD, Spherix Incorporated (NASDAQ/SPEX) announced that it will seek stockholder approval to implement a reverse stock split at a Special Meeting of Stockholders on November 17, 2008, in an effort to meet the minimum per share market price requirements for continued listing on the NASDAQ Global Market. Full Press Release»

::Aug 14:: Spherix Reports 2nd Quarter Earnings BETHESDA, MD, Spherix Incorporated (NASDAQ/SPEX) reported a net loss for the three and six months ended June 30, 2008 of $1.2 million ($0.08 per share) and $3.1 million ($0.22 per share). Full Press Release»

::July 23:: Spherix Receives NASDAQ Bid Price Deficiency Letter BETHESDA, MD, Spherix Incorporated (NASDAQ/SPEX) reported that on July 21, 2008, it received written notification from NASDAQ advising the Company that the bid price of the Company’s common stock for the last thirty (30) consecutive business days had closed below the minimum $1.00 per share required for continued listing on NASDAQ. Full Press Release»

::July 14:: Spherix Expands Phase 3 Naturlose Diabetes Trial Outside Of The U.S. BETHESDA, MD, Spherix Incorporated (NASDAQ/SPEX) reported that the Phase 3 clinical trial of its potential type 2 diabetes drug, Naturlose®, will expand outside of the United States. Full Press Release»

::MAY 14:: Spherix Reports 1st Quarter Earnings BETHESDA, MD, Spherix Incorporated (NASDAQ/SPEX) reported a net loss for the three months ended March 31, 2008 of $1.9 million, or $0.13 per share. Full Press Release»

::May 14:: Spherix Holds Annual Shareholders Meeting BETHESDA, MD. At their 2008 Annual Meeting, shareholders of Spherix Incorporated (NASDAQ/SPEX) elected the following members to the Board of Directors: Full Press Release»

::MAY 12:: Market Research Shows Spherix’s Naturlose® Readily Accepted by Diabetes Patients Meets MD’s Treatment Need BETHESDA, MD, Spherix Incorporated (NASDAQ/SPEX) reported that Naturlose, a natural sugar approved as a food ingredient in the U.S. and abroad, has been found to reduce the spikes of serum glucose that follow consumption of food (1). Full Press Release»

::April 30:: Spherix D-Tagatose To Be Supplied By Inalco S.P.A. BETHESDA, MD, Spherix Incorporated (NASDAQ/SPEX) announced today that it has signed letters of intent with Inalco S.P.A., an Italy-based manufacturer of bulk pharmaceutical ingredients, to supply a portion of the D-tagatose used in the Spherix Phase 3 clinical trial of the unique sugar as a treatment for Type 2 diabetes. Full Press Release»

::April 17:: Spherix Hires Key Employees BETHESDA, MD, Spherix Incorporated (NASDAQ/SPEX) announced the recent hire of Randy Brown as Chief of Operations. Full Press Release»

::April 3:: Spherix Reports 2007 Financial Results BETHESDA, MD, Spherix Incorporated (NASDAQ/SPEX) reported a net loss of $938,000 for the year ended December 31, 2007. Full Press Release»

2007

::Nov 29:: Growth Achieved In Spherix’s Health Sciences Consulting Business Phase 3 Clinical Trial on Track, Market Research Contracts Signed BELTSVILLE, MD, Spherix Incorporated (NASDAQ/SPEX) has recently signed contracts to provide technical and regulatory consulting services to several major consumer, food, ingredient, and pharmaceutical companies. Full Press Release»

::Nov 16:: Spherix Reports 3rd Quarter Earnings BELTSVILLE, MD, Spherix Incorporated (NASDAQ/SPEX) has reported a loss from continuing operations of $3.1 million ($0.22 per share) and $7.1 million ($0.50 per share) for the three- and nine-months ended September 30, 2007, respectively. Full Press Release»

::Aug 16:: Spherix Shareholders Support Company's Focus On Naturlose, Biotechnology Changes Approved for Board of Directors and Corporate Officers BELTSVILLE, MD, Spherix Incorporated (NASDAQ/SPEX) voted to approve the sale of the Company’s InfoSpherix subsidiary to The Active Network for $17 million in cash ($15 million at closing and $2 million following a 15-month escrow period). Full Press Release»

::Aug 14:: Spherix Reports Second Quarter Earnings Increased Losses Primarily Due to Scheduled Start of Phase 3 Clinical Trial BELTSVILLE, MD, Spherix Incorporated (NASDAQ/SPEX) has reported a second quarter 2007 loss from continuing operations of $1.9 million, or 13 cents per share, compared to a loss from continuing operations of $699,000, or 5 cents per share, in the second quarter of 2006. Full Press Release»

::Aug 9:: Spherix Launches Health Sciences Consulting Business Line Dr. Claire Kruger Tapped to Lead New Division; Will Become CEO after Sale of InfoSpherix Naturlose to Remain Spherix’s Primary Focus BELTSVILLE, MD, Spherix Incorporated (NASDAQ/SPEX) announced that it is starting a Health Sciences Division to provide technical and regulatory consulting services to biotechnology and pharmaceutical companies. Claire L. Kruger, Ph.D., has been hired to lead the new division. Full Press Release»

::June 27:: Spherix Signs Definitive Agreement For Sale Of Information Subsidiary Provides Update On Becoming A Biotech Company BELTSVILLE, MD, Spherix Incorporated (NASDAQ/SPEX) has signed the definitive agreement to sell the stock of its subsidiary, InfoSpherix Incorporated, to The Active Network Inc. Full Press Release»

::May 14:: Spherix Announces First Quarter Earnings BELTSVILLE, MD, Spherix Incorporated (NASDAQ/SPEX) reported a net loss of $2.3 million for the three months ended March 31, 2007. The $1.8 million change from that of the same period in 2006 included an increase of $1.3 million in R&D costs related to the Company’s Phase 3 clinical trial of Naturlose® as a Type 2 diabetes drug. Full Press Release»

::May 1:: Spherix Announces Start Of Phase 3 Clinical Trial BELTSVILLE, MD, Spherix Incorporated (NASDAQ/SPEX) announced today that it has begun its Phase 3 clinical trial of Naturlose® as a treatment for Type 2 diabetes. The first participants have already been enrolled and the trial has begun. The remaining subjects continue to be enrolled in the United States and Australia for the trial, which is scheduled to finish testing in early 2009. Full Press Release»

::April 26:: Spherix Signs Letter Of Intent For The Sale Of Its Information Subsidiary Will Become Exclusively a Biotech Company BELTSVILLE, MD, Spherix Incorporated (NASDAQ/SPEX) has signed a letter of intent to sell the stock of its subsidiary, InfoSpherix Incorporated, to The Active Network Inc. Terms of the deal have not been disclosed. InfoSpherix contracts with government agencies to design, host, and operate park reservation services and public service contact centers. Full Press Release»

::March 30:: SPHERIX REPORTS RECORD 2006 FINANCIAL RESULTS BELTSVILLE, MD, Spherix Incorporated (NASDAQ/SPEX) reported record revenue of $24.8 million for the year ended December 31, 2006, up 8% over 2005. The strong increase between years was the result of continued growth from InfoSpherix's (the Company's wholly-own subsidiary) popular Government Campground Reservation Business. Full Press Release»

::February 22:: INFOSPHERIX ADDS GOLF PACKAGE TO ITS RESERVEWORLD BUSINESS LINE Partnership with The Active Network Allows Integrated Solution for Parks BELTSVILLE, MD, Spherix Incorporated (NASDAQ/SPEX) is adding an integrated golf course management module to the suite of business solutions it offers to public parks agencies through its ReserveWorld business line, thanks to a technology partnership the Company has struck with The Active Network, Inc. Full Press Release»

For previous years' press releases please view the Spherix Press Release Archives.

If you need further information or have any questions, please feel free to contact our media liason at info@spherix.com.